![Craig Millian](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Craig Millian
Vorstandsvorsitzender bei
HLS THERAPEUTICS INC.
Vermögen: 43 500 $ am 30.06.2026
Profil
Craig Millian is currently Chief Executive Officer & Director at HLS Therapeutics, Inc. since 2023.
Former roles include Chief Operating Officer at Corbus Pharmaceuticals Holdings, Inc. from 2021 to 2023, Senior Vice President-Neurology & Immunology at EMD Serono, Inc. from 2016 to 2018, Vice President-Commercial at Vertex Pharmaceuticals, Inc., and a position at EMD Serono, Inc. from 2012 to 2018.
Education includes an undergraduate degree from the University of Pennsylvania and an MBA from New York University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 26.06.2026 | 14’500 ( 0.05% ) | 43 500 $ | 30.06.2026 |
Aktive Positionen von Craig Millian
| Unternehmen | Position | Beginn |
|---|---|---|
| HLS THERAPEUTICS INC. | Vorstandsvorsitzender | 01.05.2023 |
Ehemalige bekannte Positionen von Craig Millian
| Unternehmen | Position | Ende |
|---|---|---|
| CORBUS PHARMACEUTICALS HOLDINGS, INC. | Geschäftsführer | 14.04.2023 |
EMD Serono, Inc.
 EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology Develops recombinant prescription medicines | Corporate Officer/Principal | 01.12.2018 |
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | - |
Ausbildung von Craig Millian
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
68
Beziehungen ersten Grades
6
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
Vertex Pharmaceuticals, Inc.
 Vertex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops drugs for the treatment of cystic fibrosis | Health Technology |
University of Pennsylvania
 University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
New York University
 New York University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
EMD Serono, Inc.
EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology Develops recombinant prescription medicines | Health Technology |
Corbus Pharmaceuticals Holdings, Inc.
 Corbus Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases | Health Technology |
HLS Therapeutics, Inc.
 HLS Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
